EUVIMEDEUVIMED entdecken
Crossref

From regulatory approval to patient access: A comparative analysis of biosimilar market entry timelines in Japan, the USA, and the EU

Miya Kawasaki, Yuka Saino, Anri Nishizawa, Aya Hariu, Ryosuke Kuribayashi

Naunyn-Schmiedeberg's Archives of Pharmacology · 21.11.2026

DOI: 10.1007/s00210-026-06048-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 21.11.2026. Verfasst von Miya Kawasaki und 4 weiteren Autor:innen. Die Arbeit nennt 79 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kawasaki, M., Saino, Y., Nishizawa, A., Hariu, A., & Kuribayashi, R. (2026). From regulatory approval to patient access: A comparative analysis of biosimilar market entry timelines in Japan, the USA, and the EU. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-06048-4

Vancouver

Kawasaki M, Saino Y, Nishizawa A, Hariu A, Kuribayashi R. From regulatory approval to patient access: A comparative analysis of biosimilar market entry timelines in Japan, the USA, and the EU. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-06048-4

BibTeX
@article{Kawasaki2026,
  author = {Kawasaki, Miya and Saino, Yuka and Nishizawa, Anri and Hariu, Aya and Kuribayashi, Ryosuke},
  title = {From regulatory approval to patient access: A comparative analysis of biosimilar market entry timelines in Japan, the USA, and the EU},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-06048-4}
}
Kostenlos starten →